Ethoheptazine

Ethoheptazine^[1] (trade name Zactane) is an opioid analgesic from the phenazepane family. It was invented in the 1950s^[2] and is a ring expanded analogue of pethidine.^[3]

Ethoheptazine

Clinical data
Trade names	Zactane, Equagesic
Other names	Zactane
Routes of administration	Oral
ATC code	none
Legal status
Legal status	US: Schedule IV (Some preparations)
Identifiers
IUPAC name Ethyl 1-methyl-4-phenylazepane-4-carboxylate
CAS Number	77-15-6 N
PubChem CID	6469
DrugBank	DB08988 N
ChemSpider	6225 Y
UNII	3A4G3A848U
ChEMBL	ChEMBL170797 N
CompTox Dashboard (EPA)	DTXSID7023017
ECHA InfoCard	100.000.917
Chemical and physical data
Formula	C16H23NO2
Molar mass	261.365 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCC)C2(c1ccccc1)CCN(C)CCC2
InChI InChI=1S/C16H23NO2/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16/h4-6,8-9H,3,7,10-13H2,1-2H3 Y Key:WGJHHMKQBWSQIY-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Ethoheptazine produces similar effects to other opioids, including analgesia, sedation, dizziness, and nausea.^[4] It was sold by itself as Zactane, and is still available as a combination product with acetylsalicylic acid and meprobamate as Equagesic, which is used for the treatment of conditions where both pain and anxiety are present.^[5] It was also investigated for use as an antitussive.^[6]

It is no longer prescribed, as it is no longer FDA approved, and not available for United States' Pharmacy Processing. Revocation of FDA Approved Medications Status stems from a combination of efficacy vs. toxicity, and the more-varied and historically safer benzodiazepines class. Only reversal of the FDA's decision, allows removing the drug from the CSD. Ethoheptazine is not listed as a controlled substance under the Controlled Substances Act, 1970 in the United States.^[7] The controlled status (Schedule IV) of Equagesic was due to the meprobamate content.^[8][7] Regulation elsewhere varies.